Control Bionics Limited (ASX: CBL)

Market Cap	14.36M
Revenue (ttm)	5.35M
Net Income (ttm)	-5.91M
Shares Out	247.56M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,170
Open	0.0580
Previous Close	0.0580
Day's Range	0.0580 - 0.0580
52-Week Range	0.0380 - 0.1050
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About Control Bionics

Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a small portable control device that ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CBL

Financial Performance

In 2024, Control Bionics's revenue was 5.35 million, a decrease of -5.17% compared to the previous year's 5.64 million. Losses were -5.91 million, 5.02% more than in 2023.